search
Back to results

A Study of Single Ascending Dose of LEM-S401 in Healthy Participants

Primary Purpose

Cicatrix, Scar Prevention

Status
Completed
Phase
Phase 1
Locations
Korea, Republic of
Study Type
Interventional
Intervention
LEM-S401
Placebo
Sponsored by
Lemonex Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Cicatrix focused on measuring Scars, Scar prevention, Fibrosis

Eligibility Criteria

19 Years - 65 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Healthy male and female subjects aged 19 to ≤ 65 years at screening

Exclusion Criteria:

  • Significant history or clinical manifestation of any hepatic, renal, neurological, psychiatric, respiratory, endocrine, hematological, tumor, genitourinary, cardiovascular, gastrointestinal, musculoskeletal, dermatological (eg, contact dermatitis, atopic dermatitis), or other
  • History of drug abuse or positive urine drug screen at screening
  • For all female subjects, pregnant (Urine-HCG positive) or breast-feeding subjects

Sites / Locations

  • Chungbuk National University Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

LEM-S401

Placebo

Arm Description

Outcomes

Primary Outcome Measures

The safety and tolerability of LEM-S401 evaluated by incidence of adverse events
Evaluation of safety and tolerability of subcutaneous injections of LEM-S401. Examination of any incidence of adverse events.

Secondary Outcome Measures

Full Information

First Posted
January 11, 2021
Last Updated
February 14, 2023
Sponsor
Lemonex Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT04707131
Brief Title
A Study of Single Ascending Dose of LEM-S401 in Healthy Participants
Official Title
A Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Phase I Clinical Trial to Evaluate the Characteristics of the Safety, Tolerability and Pharmacokinetics of LEM-S401 in Healthy Adult Subjects
Study Type
Interventional

2. Study Status

Record Verification Date
February 2023
Overall Recruitment Status
Completed
Study Start Date
July 11, 2022 (Actual)
Primary Completion Date
October 18, 2022 (Actual)
Study Completion Date
February 3, 2023 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Lemonex Inc.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
The primary objective of the study is to assess the safety and tolerability of single dose of LEM-S401 in healthy adult subjects.
Detailed Description
This study is designed to evaluate the safety and tolerability of LEM-S401 administered as subcutaneous injection in healthy adult subjects. Overall, 18 subjects will be studied in 3 groups. Each subject will receive LEM-S401 or placebo subcutaneously.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cicatrix, Scar Prevention
Keywords
Scars, Scar prevention, Fibrosis

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
19 (Actual)

8. Arms, Groups, and Interventions

Arm Title
LEM-S401
Arm Type
Experimental
Arm Title
Placebo
Arm Type
Placebo Comparator
Intervention Type
Drug
Intervention Name(s)
LEM-S401
Intervention Description
siRNA encapsulated in DegradaBALL®
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Placebo
Primary Outcome Measure Information:
Title
The safety and tolerability of LEM-S401 evaluated by incidence of adverse events
Description
Evaluation of safety and tolerability of subcutaneous injections of LEM-S401. Examination of any incidence of adverse events.
Time Frame
Up to 16 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
19 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Healthy male and female subjects aged 19 to ≤ 65 years at screening Exclusion Criteria: Significant history or clinical manifestation of any hepatic, renal, neurological, psychiatric, respiratory, endocrine, hematological, tumor, genitourinary, cardiovascular, gastrointestinal, musculoskeletal, dermatological (eg, contact dermatitis, atopic dermatitis), or other History of drug abuse or positive urine drug screen at screening For all female subjects, pregnant (Urine-HCG positive) or breast-feeding subjects
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Lemonex Inc. Study Director
Organizational Affiliation
Lemonex Inc.
Official's Role
Study Director
Facility Information:
Facility Name
Chungbuk National University Hospital
City
Cheongju
Country
Korea, Republic of

12. IPD Sharing Statement

Plan to Share IPD
Undecided

Learn more about this trial

A Study of Single Ascending Dose of LEM-S401 in Healthy Participants

We'll reach out to this number within 24 hrs